DrugPatentWatch Database Preview
Patent: 9,335,320
Try a free trial
See Plans and Pricing
Summary for Patent: 9,335,320
| Title: | Combinations of phosphoinositide 3-kinase inhibitor compounds and chemotherapeutic agents for the treatment of hematopoietic malignancies |
| Abstract: | Combinations of PI3K inhibitor compounds having Formula I and chemotherapeutic agents, including stereoisomers, geometric isomers, tautomers, metabolites and pharmaceutically acceptable salts thereof, are useful for treating hematopoietic malignancies. Methods of using such combinations for in vitro, in situ, and in vivo diagnosis, prevention or treatment of such disorders in mammalian cells, or associated pathological conditions, are disclosed ##STR00001## |
| Inventor(s): | Ebens, Jr.; Allen J. (San Carlos, CA), Friedman; Lori (San Carlos, CA) |
| Assignee: | Genentech, Inc. (South San Francisco, CA) |
| Application Number: | 13/968,202 |
| Patent Claims: | see list of patent claims |
Details for Patent 9,335,320
| Applicant | Tradename | Biologic Ingredient | Dosage Form | BLA | Number | Approval Date | Patent No. | Assignee | Estimated Patent Expiration | Status | Orphan | Source |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Genentech | RITUXAN | rituximab | VIAL | 103705 | 001 | 1997-11-26 | Try a Free Trial | Genentech, Inc. (South San Francisco, CA) | 2036-05-13 | RX | search | |
| >Applicant | >Tradename | >Biologic Ingredient | >Dosage Form | >BLA | >Number | >Approval Date | >Patent No. | >Assignee | >Estimated Patent Expiration | >Status | >Orphan | >Source |
International Patent Family for US Patent 9,335,320
| Country | Patent Number | Publication Date |
|---|---|---|
| Australia | 2010224125 | Aug 04, 2011 |
| Australia | 2010224125 | May 14, 2015 |
| Canada | 2753285 | Sep 16, 2010 |
| China | 102369011 | Mar 07, 2012 |
| European Patent Office | 2405916 | Feb 07, 2018 |
| European Patent Office | 2405916 | Jan 18, 2012 |
| >Country | >Patent Number | >Publication Date |
